Alphatec Holdings, Inc. (NASDAQ:ATEC) Shares Sold by Fmr LLC

Fmr LLC decreased its position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 49.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,253 shares of the medical technology company’s stock after selling 8,908 shares during the period. Fmr LLC’s holdings in Alphatec were worth $51,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Magnetar Financial LLC acquired a new position in shares of Alphatec in the 2nd quarter valued at $10,957,000. First Eagle Investment Management LLC acquired a new position in Alphatec in the second quarter valued at $1,071,000. Lighthouse Investment Partners LLC raised its holdings in shares of Alphatec by 257.5% in the second quarter. Lighthouse Investment Partners LLC now owns 208,594 shares of the medical technology company’s stock valued at $2,180,000 after buying an additional 150,244 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of Alphatec by 11.3% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company’s stock worth $16,280,000 after buying an additional 297,850 shares during the period. Finally, AlphaCentric Advisors LLC purchased a new position in shares of Alphatec during the third quarter worth about $2,057,000. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Alphatec Trading Up 1.2 %

Shares of ATEC opened at $9.23 on Wednesday. Alphatec Holdings, Inc. has a twelve month low of $4.88 and a twelve month high of $17.34. The firm has a market capitalization of $1.31 billion, a P/E ratio of -7.21 and a beta of 1.38. The firm’s 50-day moving average is $8.53 and its two-hundred day moving average is $8.09. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $13.00 price objective on shares of Alphatec in a research note on Thursday, October 31st. Lake Street Capital decreased their price target on Alphatec from $32.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a research note on Thursday, October 31st. Barclays upped their price objective on shares of Alphatec from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 19th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $20.00 price target on shares of Alphatec in a research note on Friday, August 30th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Alphatec currently has a consensus rating of “Moderate Buy” and an average price target of $17.11.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.